玻璃体内注射贝伐单抗作为抗血管内皮生长因子用于治疗增殖性糖尿病视网膜病变的并发症
Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy.
作者信息
Arevalo J Fernando
机构信息
Retina Division, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA & The Vitreoretinal Division, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia & Faculty of Health Sciences, Stellenbosch University, South Africa.
出版信息
Med Hypothesis Discov Innov Ophthalmol. 2013 Spring;2(1):20-4.
Abstract
Vascular endothelial growth factor (VEGF) has been shown to be an endothelial cell-specific mitogen and an angiogenic inducer in a variety of in vitro and in vivo models. Furthermore, it has been demonstrated to increase retinal vessel permeability by increasing the phosphorylation of tight junction proteins. Recent work has found elevated levels of VEGF in ocular fluids of patients with proliferative diabetic retinopathy (PDR). Thus, it makes sense to consider anti-VEGF treatments in the management of PDR. The purpose of the current research is to determine if intravitreal bevacizumab as anti-VEGF is helpful in the management of complications of PDR.
摘要
血管内皮生长因子（VEGF）在多种体外和体内模型中已被证明是一种内皮细胞特异性促有丝分裂原和血管生成诱导剂。此外，它已被证实可通过增加紧密连接蛋白的磷酸化来提高视网膜血管通透性。最近的研究发现，增殖性糖尿病视网膜病变（PDR）患者眼内液中VEGF水平升高。因此，在PDR的治疗中考虑抗VEGF治疗是合理的。本研究的目的是确定玻璃体内注射贝伐单抗作为抗VEGF药物是否有助于治疗PDR的并发症。
相似文献
1
Intravitreal bevacizumab as anti-vascular endothelial growth factor in the management of complications of proliferative diabetic retinopathy.
Med Hypothesis Discov Innov Ophthalmol. 2013 Spring;2(1):20-4.
2
Effect of intravitreal bevacizumab on vascular endothelial growth factor expression in patients with proliferative diabetic retinopathy.
Yonsei Med J. 2011 Jan;52(1):151-7. doi: 10.3349/ymj.2011.52.1.151.
3
Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy.
Am J Ophthalmol. 2012 May;153(5):896-902.e1. doi: 10.1016/j.ajo.2011.10.006. Epub 2012 Jan 20.
4
A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy.
Br J Ophthalmol. 2012 Apr;96(4):587-90. doi: 10.1136/bjophthalmol-2011-301005. Epub 2012 Jan 29.
5
A review of clinical trials of anti-VEGF agents for diabetic retinopathy.
Graefes Arch Clin Exp Ophthalmol. 2010 Jul;248(7):915-30. doi: 10.1007/s00417-010-1315-z. Epub 2010 Feb 20.
6
The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.
Drugs Context. 2018 Aug 13;7:212532. doi: 10.7573/dic.212532. eCollection 2018.
7
ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
Retina. 2015 Oct;35(10):1931-42. doi: 10.1097/IAE.0000000000000723.
8
Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
Pharmaceutics. 2021 Jul 26;13(8):1137. doi: 10.3390/pharmaceutics13081137.
9
Optical coherence tomography angiography analysis of macular vessel density before and after anti-VEGF therapy in eyes with diabetic retinopathy.
Int Ophthalmol. 2019 Oct;39(10):2361-2371. doi: 10.1007/s10792-019-01076-x. Epub 2019 May 22.
10
Vascular endothelial growth factor in plasma and vitreous fluid of patients with proliferative diabetic retinopathy patients after intravitreal injection of bevacizumab.
Am J Ophthalmol. 2012 Feb;153(2):307-313.e2. doi: 10.1016/j.ajo.2011.08.006. Epub 2011 Oct 7.
引用本文的文献
1
Postnatal hyperglycemia alters amino acid profile in retinas (model of Phase I ROP).
iScience. 2023 Sep 22;26(10):108021. doi: 10.1016/j.isci.2023.108021. eCollection 2023 Oct 20.
2
Review of Studies Comparing Panretinal Photocoagulation and Anti-Vascular Endothelial Growth Factor Therapy in the Treatment of Proliferative Diabetic Retinopathy.
Cureus. 2022 Feb 21;14(2):e22471. doi: 10.7759/cureus.22471. eCollection 2022 Feb.
3
Novel Role of Prereplication Complex Component Cell Division Cycle 6 in Retinal Neovascularization.
Arterioscler Thromb Vasc Biol. 2022 Apr;42(4):407-427. doi: 10.1161/ATVBAHA.121.317182. Epub 2022 Mar 3.
4
The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration.
Int J Mol Sci. 2018 Jan 1;19(1):110. doi: 10.3390/ijms19010110.
5
APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.
Retina. 2019 Feb;39(2):265-273. doi: 10.1097/IAE.0000000000001952.
6
FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.
Cell Rep. 2017 Feb 14;18(7):1606-1613. doi: 10.1016/j.celrep.2017.01.014.
7
The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects.
Turk J Ophthalmol. 2016 Oct;46(5):221-225. doi: 10.4274/tjo.82542. Epub 2016 Oct 17.
8
Neuroinflammatory responses in diabetic retinopathy.
J Neuroinflammation. 2015 Aug 7;12:141. doi: 10.1186/s12974-015-0368-7.
9
Changes in the retinal vascular network morphology (diameter and tortuosity) after administration of intravitreal bevacizumab in a patient with ischaemic branch retinal vein occlusion.
Case Rep Ophthalmol. 2014 Dec 4;5(3):411-5. doi: 10.1159/000368343. eCollection 2014 Sep.
本文引用的文献
1
Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Ophthalmology. 2012 Apr;119(4):789-801. doi: 10.1016/j.ophtha.2011.12.039. Epub 2012 Feb 11.
2
Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture.
J Ophthalmol. 2011;2011:584238. doi: 10.1155/2011/584238. Epub 2011 Mar 30.
3
The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.
Ophthalmology. 2011 Sep;118(9):1819-26. doi: 10.1016/j.ophtha.2011.02.018. Epub 2011 May 5.
4
A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
Ophthalmology. 2011 Jun;118(6):1107-18. doi: 10.1016/j.ophtha.2011.02.045. Epub 2011 May 6.
5
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
6
Intravitreal Bevacizumab (Avastin(®)) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture.
Curr Diabetes Rev. 2010 Sep;6(5):313-22. doi: 10.2174/157339910793360842.
7
Global estimates of the prevalence of diabetes for 2010 and 2030.
Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007. Epub 2009 Nov 6.
8
Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Ophthalmology. 2009 Aug;116(8):1488-97, 1497.e1. doi: 10.1016/j.ophtha.2009.03.016. Epub 2009 Jul 9.
9
Intravitreal bevacizumab for diabetic retinopathy.
Curr Diabetes Rev. 2009 Feb;5(1):39-46. doi: 10.2174/157339909787314121.
10
Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up.
Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):735-43. doi: 10.1007/s00417-008-1034-x. Epub 2009 Feb 3.
Zotero 插件